Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21576635 | 0.73 | CYP11B2 (0.42) | CYP11B2 | |
| SCHEMBL22751742 | 0.72 | — | — | |
| SCHEMBL3806985 | 0.72 | PLAU (0.41) | — | |
| SCHEMBL19250471 | 0.71 | CYP11B2 (0.45) | CYP11B2 | |
| SCHEMBL21831999 | 0.70 | DAPK3 (0.38) | — | |
| SCHEMBL21832037 | 0.69 | CYP11B2 (0.44) | CYP11B2 | |
| SCHEMBL22151080 | 0.69 | CYP11B2 (0.44) | CYP11B2 | |
| SCHEMBL22908471 | 0.69 | CYP11B2 (0.44) | CYP11B2 | |
| SCHEMBL7586414 | 0.69 | DRD2 (0.40) | — | |
| SCHEMBL23364990 | 0.68 | CYP2C9 (0.40) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475262-B1 | BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASE, CARDIOVASCULAR DISEASES AND FIBROTIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-24 | — | — | EP | disclosed |
| US-10858342-B2 | Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-08 | — | — | US | disclosed |
| US-10858342-B2 | Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-08 | — | — | US | disclosed |
| US-20200109131-A1 | BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASES, CARDIOVASCULAR DISEASES AND FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858342-B2 | Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases | REN, AGTR1, AGTR2 | CYP11B2 61/4885 |
| US-20200109131-A1 | BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASES, CARDIOVASCULAR DISEASES AND FIBROTIC DISEASES | REN, AGTR1, AGTR2 | CYP11B2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.